Pharmaceutical - Financial, Novartis

Filter

Current filters:

FinancialNovartis

Popular Filters

1 to 25 of 38 results

Novartis’ strong third-qtr boosted by sale of Idenix stake

Novartis’ strong third-qtr boosted by sale of Idenix stake

28-10-2014

Swiss pharma major Novartis this morning reported that sales for the third quarter of 2014 rose 4% to…

AlconFinancialNovartisPharmaceuticalSandozSwitzerland

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Novartis suspends commissioning of new Russian plant

13-10-2014

Swiss pharma major Novartis has decided to suspend the commissioning of its new Russian plant, which…

FinancialNovartisPharmaceuticalProductionRussia

Major step forward for multiple sclerosis treatment in New Zealand

13-10-2014

Funding for newer and more effective multiple sclerosis (MS) treatments has been approved by PHARMAC,…

Biogen IdecCopaxoneFinancialGilenyaHealthcareNeurologicalNew ZealandNovartisPharmaceuticalTeva Pharmaceutcal IndustriesTysabri

Multiple sclerosis treatments funding proposal in New Zealand

Multiple sclerosis treatments funding proposal in New Zealand

07-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving…

Biogen IdecFinancialGilenyaNeurologicalNew ZealandNovartisPharmaceuticalTysabri

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

17-07-2014

Switzerland’s Novartis – now the world’s largest pharmaceutical company by sales - this morning…

AlconFinancialNovartisPharmaceuticalSandoz

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Novartis 1st-qtr net profit flat, sales shy of forecasts

Novartis 1st-qtr net profit flat, sales shy of forecasts

24-04-2014

Swiss drug major Novartis posted a solid set of first-quarter 2014 financials this morning, showing that…

AlconFinancialNovartisPharmaceuticalSandoz

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

Novartis delivers strong sales, despite generic erosion, but misses expectations

Novartis delivers strong sales, despite generic erosion, but misses expectations

29-01-2014

Swiss drug major Novartis this morning reported that fourth-quarter net income rose 2% to $2.06 billion,…

FinancialNovartisPharmaceutical

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Novartis highlights growth prospects, boasting significant pipeline progress

Novartis highlights growth prospects, boasting significant pipeline progress

22-11-2013

In an upbeat statement ahead of its annual investor day in London today (November 22), Swiss pharma giant…

FinancialNovartisPharmaceuticalResearch

Vectura posts flat sales and increased loss for first-half 2013

19-11-2013

UK-based developer of inhaled therapies Vectura Group has announced its unaudited interim results for…

FinancialNovartisPharmaceuticalRespiratory and PulmonaryVectura

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Novartis 2nd-quarter in line with analysts' forecasts

17-07-2013

Novartis 2nd-quarter in line with analysts' forecasts

FinancialGenericsNovartisPharmaceutical

Novartis reports 7% rise in 1st-qtr net income, beating expectations

24-04-2013

Swiss drug giant Novartis (NOVN: VX) this morning reported first-quarter 2013 financial results showing…

FinancialManagementNovartisPharmaceutical

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

1 to 25 of 38 results

Back to top